about
C-C motif chemokine ligand 17Wiskott-Aldrich syndromeVimentinToll-like receptor 3A disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 13Chemokine (C-C motif) ligand 12Glyceraldehyde-3-phosphate dehydrogenaseCaspase 1Aquaporin 4Toll-like receptor 2Chemokine (C-C motif) ligand 4Chemokine (C-C motif) ligand 7Chemokine (C-C motif) ligand 11Chemokine (C-C motif) ligand 20Chemokine (C-C motif) ligand 21A (serine)Chemokine (C-C motif) ligand 22Chemokine (C-X3-C motif) ligand 1Predicted gene 2023Toll-like receptor 4Class II transactivatorChemokine (C-C motif) ligand 5Cell division cycle 42Syntaxin 11Fc fragment of IgA receptorMajor histocompatibility complex, class II, DP alpha 1Interleukin 12 receptor subunit beta 1Enah/Vasp-likeCDC42 effector protein 2CDC42 effector protein 4Syntaxin 4Steroidogenic acute regulatory proteinCD47 moleculeSynaptotagmin binding cytoplasmic RNA interacting proteinCD58 moleculeC-C motif chemokine ligand 24C-C motif chemokine ligand 25C-C motif chemokine ligand 16C-C motif chemokine ligand 23C-C motif chemokine ligand 18C-C motif chemokine ligand 14
P682
DAPK-ZIPK-L13a axis constitutes a negative-feedback module regulating inflammatory gene expressionCharacterization of the 5'-flanking region and regulation of expression of human anion exchanger SLC26A6IRT-1, a novel interferon-gamma-responsive transcript encoding a growth-suppressing basic leucine zipper proteinHuman astrocytes express aquaporin-1 and aquaporin-4 in vitro and in vivoFunctional characterization of the human dendritic cell immunodeficiency associated with the IRF8(K108E) mutation
P921
Q1069599-ECE7D5D7-A82C-4B45-80ED-471A9F2F5278Q14863973-73AB1B76-8D09-43F0-BF8B-FE7876967ED3Q14864871-0BDAF44B-D13D-475A-8DB9-F25D5585513BQ14866248-E7C4A6D5-FDC2-4C5E-9881-ECAFEC7BA3E3Q14873947-9FECE8F5-F6A9-4EF3-9EF3-9DA9BE301B41Q14885647-A0888642-FE64-4621-96E3-6AA1E6124DE2Q14890093-39F9E9B5-B1D3-4E6F-84A9-06147EF35E51Q14901975-9F167008-3F05-4FD3-8426-32925683780BQ14901975-A2184D39-A3A8-4DFA-B8DF-56ADFC8338AFQ14902507-077D2217-6D63-4831-979F-805C4362BE1DQ14907444-482D1610-27DF-4295-933F-FE23C149D5C3Q14907553-78803A06-0D70-4097-A3AA-C2B178422138Q14907644-B7CB37E6-03CA-4A15-84D6-7D718528CB8AQ14907652-52CCBE7D-3407-4E6F-B7E1-7EE4B2E475A0Q14907659-261EC855-06A1-465F-99B2-DACF5512B384Q14907767-0EA742BB-B555-4EEB-88A5-B7E22FCBD8E9Q14907775-EA09714F-C13F-4DC2-8D49-AE13451BE2A4Q14907782-695E8746-7517-4CEB-9D5A-AC65A22070F3Q14907797-F4333F85-53A8-4ECB-8F98-AAE25FD0377DQ14914104-637167DA-7820-4B71-918C-344043A1A689Q14914111-CF336E46-0AD8-458D-AE5D-C8C88D08F5B1Q14916107-24B55524-6D7A-4DA9-BA18-6218A9CDBE95Q14916107-97718047-F94D-4221-8002-8249D51E3EDEQ15311709-5040D800-4812-4E5C-86ED-32E46179A048Q15314392-DE37D86A-8A44-449E-98E7-89FD5ADA7CFCQ21101404-81E3E9EA-FFDD-4D7D-8160-D9C41CBADA00Q21102663-A5F24CEF-D3C0-40A8-A1B8-F8B46383049DQ21103375-E3777F36-3663-4260-876F-223A4F6C0FA9Q21104898-A2D748BB-919D-4AF9-9233-4F96EFFB01F9Q21105464-05F58D9B-1C58-4A21-8950-EFD539B0B236Q21105469-99DED103-8B85-4DD4-98F2-9F3DB0BFC656Q21106672-111E069B-033B-446F-ABD1-6B7FE52B62B4Q21107952-804A06AE-F6A7-4850-841E-0EB9A2FDCBA0Q21108354-026AA661-4CA8-433B-8EB0-D7A524525D99Q21111368-D3263BEF-5903-4692-B2A4-7837560CEFB2Q21113587-DE248AB7-AA43-45AC-AB72-DE9252F07F63Q21113917-B52B4D8F-DDB2-4D62-AA2B-FB245559F1D3Q21113920-666BFA8B-9D06-4AC6-B4D2-AE698DCA900EQ21113921-4E055DA3-5384-4134-B8F3-7790C8E87B1BQ21113933-8050FC7B-94E6-495E-A61D-5B4795F18570
P682
description
Any process that results in a ...... mber of the type II interferon
@en
biologisch proces
@nl
name
cellular response to interferon-gamma
@en
type
label
cellular response to interferon-gamma
@en
altLabel
GO:0071346
@en
cellular response to immune interferon
@en
prefLabel
cellular response to interferon-gamma
@en
P2888
P686
GO:0071346